MiniMed Group, Inc. (MMED) has received a new Hold rating, initiated by Piper Sandler analyst, Matthew O’Brien.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Matthew O’Brien has given his Hold rating due to a combination of factors tied to MiniMed’s current positioning and execution outlook. He acknowledges that the company has built a sizable global diabetes franchise with strong physician acceptance of its dosing algorithm and a broad presence in many international markets, and he sees potential in the upcoming suite of products that could improve MiniMed’s competitive stance over time.
At the same time, he notes that MiniMed still trails key rivals on product design and user-friendliness, which may constrain growth and leave financial targets vulnerable in the near to medium term. He also flags meaningful risks from intense competitive dynamics, growing international threats from U.S. peers, and a history of product delays, and therefore prefers to wait for clearer evidence of successful execution before taking a more positive view on the shares.